Artax Biopharma Inc

Our CBO, Maria Nichol, attended the Bio-Europe Spring hosted by EBD Group in Milan, Italy. She had a great time engaging in stimulating conversations with existing and new industry players on the ground earlier this week! #BIOEuropeSpring

Did you know that 1 in 10 individuals are affected by an #AutoimmuneDisease? This #AutoimmuneDiseaseAwarenessMonth, we're honoring patients living with an autoimmune condition. At Artax, we are developing first-in-class oral therapies to modulate T cell-mediated activation and restore healthy immune responses to address a broad range of autoimmune diseases, including #psoriasis and #AtopicDermatitis. Learn more about our approach: https://bit.ly/3Fpxqpa

In case you missed it, our Chief Scientific Officer, Christopher VanDeusen, Ph.D., presented new data on our Nck modulators at this year's American Academy of Dermatology Annual Meeting. Thank you for a great meeting filled with engaging discussions, and the opportunity to connect with other academic and industry leaders! Catch up on our latest data here: https://bit.ly/4bJKhP2

Our Chief Scientific Officer, Christopher VanDeusen, Ph.D., is presenting compelling new preclinical data at this year's American Academy of Dermatology Annual Meeting on the potential of our Nck modulators to reduce inflammation in models of #AtopicDermatitis. Catch up on the data in our press release: https://lnkd.in/eVTGUiJ8

Will you be attending the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida? Join us on March 8th as our Chief Scientific Officer, Christopher VanDeusen, Ph.D., presents #ClinicalData from our lead Nck modulator’s evaluation in atopic dermatitis models. Read more in our press release: https://bit.ly/4brcXfz

This Follow Friday, we present Emma Guttman, Health System Chair and professor at the Icahn School of Medicine at Mt. Sinai. Dr. Guttman's posts offer a great way to stay current on the latest in Atopic Dermatitis research and practice.?Be it this recent post on the Lancet review, or the upcoming summit on Atopic Dermatitis and Alopecia Areata at AAD presented by the International Eczema Council, we highly recommend following Dr. Guttman if atopic dermatitis is part of your proactive or research interest.

Happy International Day of Women and Girls in Science! Our own VP of Clinical Operations, Suzanne Crowley has some words about her work with Artax. "Conducting scientific inquiry requires curiosity, patience, attention to detail, open-mindedness, persistence, integrity, adaptability, and sometimes courage! In my own work as Vice President Clinical Operations at Artax Biopharma, I aim to deliver the best science to help patients with autoimmune diseases."

Our own Andre Hoekema, Board Chair at Artax, had some words about Artax and the promise of Nck blockers as a new universal oral approach for treating autoimmune disorders. https://lnkd.in/dB85yQdC

The T cell receptor (or TCR) is central to healthy T cell function and a regulated immune system. When the immune system malfunctions and the TCR becomes dysregulated, T cells behave abnormally, attacking a patient’s own tissues and organs, resulting in autoimmune diseases. Nck is an adaptor protein which plays a direct role in T cell mediated diseases. Nck directly amplifies TCR responses and reduces the dysregulated TCR signaling which contributes to T cell mediated diseases. Artax Biopharma is developing first-in-class, oral small molecules that inhibit Nck binding to the TCR. Through this novel mechanism, Artax’s Nck inhibitors selectively modulate Nck’s amplification of the TCR, resulting in a lower T cell activation and less T cell response and allowing patients to receive treatment while avoiding the risks that come with immunosuppression.

"I remember clearly the first time I read the seminal Science Translational Medicine paper from the Alarcon laboratory in 2016 discussing Nck and its role in T cell receptor (TCR) signaling in the winter of 2017.?The implications of immune modulation rather than suppression were enormous, and I knew I had to become involved with the project.?Designing AX-158 allowed us to have in hand an ideal candidate molecule from a pharmacology perspective, and in parallel we spent resources refining our?understanding of?the biology of Nck modulation and developing a compelling translational medicine story.?A key moment in this journey was the design of the cytokine response curve-shift experiment, which for the first time really clearly demonstrated the functional impact of excluding Nck from the activated TCR complex.?This insight we had allowed us to sharpen the focus of our efforts to reveal crucial elements around this novel biology which until this point had been addressed as a conditional inhibitor.?As our latest step in this journey, last week we announced the clinical validation of first in class Nck modulator AX-158 in patients with psoriasis. Making something like this happen is what we dream about in our business, and we look forward to seeing what longer treatment might offer for patients." - Christopher VanDeusen Ph.D., CSO Artax Biopharma Reach out to us at [email protected] to get access to the results - we'd love to hear from you. And read our press release here: https://lnkd.in/eHTH82pF